In this symposium, Prof. Georg Schett, Prof. Denis Poddubnyy, Dr. Raj Sengupta and Prof. Maria-Antonietta D’Agostino discuss:
- Impact and associated burden of structural damage progression on patients with PsA and axSpA
- Importance of imaging to detect inflammation and tissue damage in PsA and axSpA and allow earlier diagnosis and treatment initiation before structural damage occurs
- Benefits of initiating treatment with biologics early in the disease course to potentially improve outcomes and reduce structural damage progression in patients with PsA and axSpA
How to visualize inflammation and tissue response in PsA and axSpA?
Prof. Georg Schett discusses tissue inflammation preceding structural damage and repair mechanisms in PsA and axSpA, and provides an overview on novel imaging in both diseases.
Disease modification in axSpA – what does the future hold?
Prof. Denis Poddubnyy discusses disease modification, currently approved treatments in axSpA, and introduces the SURPASS study, which is evaluating the effect of secukinumab on structural damage progression in ankylosing spondylitis compared with an adalimumab biosimilar.
How does structural damage progression impact patients?
Dr. Raj Sengupta discusses the clinical practice perspective, highlighting the effects of structural damage progression on patient function/quality of life, and the need for early treatment to prevent structural damage.
Can ultrasound make the invisible visible in PsA?
Prof. Maria-Antonietta D’Agostino discusses the use of power Doppler ultrasonography (PDUS) and the effect of secukinumab on synovitis and enthesitis in patients with PsA from the ULTIMATE study.
Making the invisible visible in PsA and axSpA (full symposium and Q&A sessions)
To watch the Q&A sessions go to 29:50 and 1:05:55.
